Company Overview
We are pioneering next generation immunotherapies to address critical unmet needs in the treatment of cancer and autoimmune diseases.
Janux is a clinical-stage company developing precision-engineered immunotherapies that have the potential to generate potent and durable immune responses without causing systemic safety issues. Janux is using its TRACTr, TRACIr and ARM platforms to engineer novel drug candidates that are designed to overcome the traditional limitations associated with contemporary immunotherapies.
Our goal at Janux is to provide patients with safe and effective drugs that direct and guide their immune system to eradicate disease while minimizing safety concerns.
Since our founding in 2017, Janux has successfully established a collaborative culture that encourages scientific creativity within the bounds of our data-driven decision-making philosophy. We closed our initial public offering (IPO) in June of 2021 and brought our first program to the clinic in the second half 2022.